AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · IEX Real-Time Price · USD
3.970
-0.040 (-1.00%)
At close: Apr 23, 2024, 4:00 PM
4.070
+0.100 (2.52%)
After-hours: Apr 23, 2024, 7:41 PM EDT
AbCellera Biologics Market Cap
AbCellera Biologics has a market cap or net worth of $1.16 billion as of April 23, 2024. Its market cap has decreased by -45.25% in one year.
Market Cap
1.16B
Enterprise Value
447.98M
1-Year Change
-45.25%
Ranking
Category
Stock Price
$3.97
Market Cap Chart
Since the IPO on December 11, 2020, AbCellera Biologics's market cap has decreased from $5.33B to $1.16B, a decrease of -78.18%. That is a compound annual growth rate of -36.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 22, 2024 | 1.17B | 3.62% |
| Apr 19, 2024 | 1.13B | -1.02% |
| Apr 18, 2024 | 1.14B | -0.25% |
| Apr 17, 2024 | 1.15B | -3.21% |
| Apr 16, 2024 | 1.19B | -3.11% |
| Apr 15, 2024 | 1.22B | -3.69% |
| Apr 12, 2024 | 1.27B | -0.91% |
| Apr 11, 2024 | 1.28B | -1.79% |
| Apr 10, 2024 | 1.31B | -5.71% |
| Apr 9, 2024 | 1.38B | 5.35% |
| Apr 8, 2024 | 1.31B | 3.45% |
| Apr 5, 2024 | 1.27B | -1.36% |
| Apr 4, 2024 | 1.29B | 0.45% |
| Apr 3, 2024 | 1.28B | 1.39% |
| Apr 2, 2024 | 1.26B | -2.71% |
| Apr 1, 2024 | 1.30B | -1.98% |
| Mar 28, 2024 | 1.33B | 0.89% |
| Mar 27, 2024 | 1.31B | 4.67% |
| Mar 26, 2024 | 1.26B | -6.33% |
| Mar 25, 2024 | 1.34B | -0.22% |
| Mar 22, 2024 | 1.34B | -2.55% |
| Mar 21, 2024 | 1.38B | -0.43% |
| Mar 20, 2024 | 1.38B | 2.83% |
| Mar 19, 2024 | 1.35B | 0.22% |
| Mar 18, 2024 | 1.34B | -2.55% |
View and export this data all the way back to 2020.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Phreesia | 1.21B |
| Kiniksa Pharmaceuticals | 1.19B |
| Deciphera Pharmaceuticals | 1.19B |
| Spyre Therapeutics | 1.17B |
| Prothena Corporation | 1.14B |
| MannKind | 1.13B |
| Xencor | 1.12B |
| AtriCure | 1.12B |